Neuroprotective efficacy of estrogen in experimental spinal cord injury in rats
- PMID: 20633113
- PMCID: PMC3127450
- DOI: 10.1111/j.1749-6632.2009.05357.x
Neuroprotective efficacy of estrogen in experimental spinal cord injury in rats
Abstract
Spinal cord injury (SCI) leads to neurological deficits and motor dysfunction. Methylprednisolone, the only drug used for treating SCI, renders limited neuroprotection and remains controversial. Estrogen is one of the most potent multiactive neuroprotective agents and it is currently under investigation in our laboratory for its efficacy in SCI. The present review briefly summarizes our earlier findings on the therapeutic potential of pharmacological/supraphysiological levels of estrogen in SCI and outlines our ongoing research, highlighting the efficacy of physiological levels of estrogen against neuronal injury, axonal degeneration, and gliosis and also the molecular mechanisms of such neuroprotection in experimental SCI. Furthermore, our ongoing studies designed to explore the different translational potential of estrogen therapy suggest that this multiactive steroid may act as an adjunct therapy to promote angiogenesis, thus enhancing the functional recovery following chronic SCI. Taken together, these studies confirm that estrogen is a potential therapeutic agent for treating SCI.
References
-
- Mayo Foundation for Medical Education and Research (MFMER) Spinal Cord Injury. Vol. 2009 Spinal Cord Injury: Causes.
-
- Miller SM. Methylprednisolone in acute spinal cord injury: a tarnished standard. Journal of Neurosurgical Anesthesiology. 2008;20:140–142. - PubMed
-
- Rozet I. Methylprednisolone in acute spinal cord injury: is there any other ethical choice? Journal of Neurosurgical Anesthesiology. 2008;20:137–139. - PubMed
-
- Hadley MN, et al. Guidelines for the management of acute cervical spine and spinal cord injuries. Clinical Neurosurgery. 2002;49:407–498. - PubMed
-
- Faden AI, Stoica B. Neuroprotection: challenges and opportunities. Archives of Neurology. 2007;64:794–800. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
